药物改变睑脂脂质组成缓解Awat2-/-小鼠干眼表型
本研究在Awat2-/-小鼠蒸发型干眼模型中,系统给予SOAT1抑制剂ATR101(nevanimibe)抑制胆固醇酯合成。结果显示药物改变睑脂理化性质、降低融化温度并增加流动性,减少睑板腺导管阻塞并保留腺体形态,同时延长泪膜破裂时间、改善泪膜稳定性并保护角膜完整性。结论提示靶向睑脂生成代谢重塑是治疗睑板腺功能障碍相关蒸发型干眼的潜在策略。
要点
- ATR101抑制SOAT1减少胆固醇酯合成,改变Awat2-/-小鼠睑脂理化性质。
- 治疗组睑板腺导管阻塞减轻、腺体形态保留,泪膜破裂时间延长。
- 药物干预改善泪膜稳定性并保护角膜完整性。
核心结论
- 药物干预睑脂生成可纠正Awat2缺陷睑板腺的致病性脂质失衡,改善泪膜和睑板腺功能。
研究设计与样本
- 研究在Awat2-/-小鼠(蒸发型干眼动物模型)中系统给予ATR101(nevanimibe),一种选择性SOAT1抑制剂。
- 分析睑脂脂质组成、睑板腺形态、泪膜破裂时间和角膜完整性,并与未治疗对照比较。
主要发现
- 药物干预改变睑脂理化性质,降低其融化温度并增加脂质流动性。
- 治疗组睑板腺导管阻塞减少,睑板腺形态得以保留。
- 与未治疗Awat2-/-小鼠相比,治疗组泪膜破裂时间延长、泪膜稳定性改善、角膜完整性保留。
临床怎么用
- 提示靶向胆固醇酯合成的药物干预可能成为睑板腺功能障碍和蒸发型干眼的治疗策略。
局限性
- 研究为Awat2-/-小鼠动物模型,结果向人类临床转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Meibomian glands (MGs) produce lipids that stabilize the tear film and maintain ocular surface homeostasis. Dysfunction of MG lipid secretion is a major cause of evaporative dry eye (EDE). The purpose of this study was to test whether pharmacologic modulation of meibum lipid biosynthesis could improve the physicochemical properties of meibum and thereby slow the progression of EDE in a mouse model of the disease. METHODS: Awat2-/- mice, an animal model of EDE, were treated systemically with ATR101 (nevanimibe), a selective sterol O-acyltransferase 1 (SOAT1) inhibitor that suppresses cholesteryl ester (CE) synthesis. Meibum lipid composition, MG morphology, tear film breakup time, and corneal integrity were analyzed and compared with untreated controls to monitor disease progression. RESULTS: Pharmacologic intervention in the CE biosynthesis in Awat2-/- mice altered the physicochemical properties of meibum, decreasing its melting temperature and increasing lipid fluidity. Treated mice exhibited reduced MG ductal obstruction and preservation of MG morphology. These changes were accompanied by prolonged tear film breakup time, improved tear film stability, and preserved corneal integrity compared with untreated Awat2-/- mice. CONCLUSIONS: Pharmacologic intervention in meibogenesis corrects a pathogenic lipid imbalance in Awat2-deficient MGs and improves tear film and MG function. These findings identify lipid metabolic remodeling of meibum as a mechanistically grounded therapeutic strategy for obstructive MG dysfunction and evaporative dry eye.
引用
- Widjaja-Adhi MAK, Chung C, Lapierre-Landry M, et al. Pharmacologic Alteration of Meibum Lipid Composition Alleviates Dry Eye Phenotype in Awat2-/- Mice. Invest Ophthalmol Vis Sci. 2026. PMID: 42307183. doi:10.1167/iovs.67.6.34
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。